Pharmaceutical giant Bristol Myers Squibb (BMY) is getting a stock boost after beating second quarter earnings expectations on the top and bottom lines and raising its full-year guidance. Yahoo Finance senior health reporter Anjalee Khemlani digs into the earnings report and some of Bristol Myers Squibb's cost-cutting measures. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
